News
Axxam and B’SYS partner to expand access to validated ion channel cell lines for high-throughput electrophysiology
4 September 2025
Milan, Italy and Witterswil, Switzerland – Axxam S.p.A., a premier provider of integrated early drug discovery services, and B’SYS GmbH, a specialist in ion channel biology, are pleased to announce a strategic collaboration focused on enabling access to validated ion channel cell lines for hit and lead identification through high-throughput electrophysiological screening.
B’SYS offers an extensive catalogue of engineered cell lines expressing a wide range of ion channels. Through this collaboration, Axxam will apply its deep expertise in biology and high-throughput screening to validate selected B’SYS cell lines on automated patch clamp platforms, including Axxam’s SP384 systems.
This joint initiative provides pharmaceutical and biotech clients with a unique advantage: the ability to obtain validated, high-quality ion channel cell lines suitable for demanding drug discovery applications. These validated lines will undergo rigorous performance-based testing to ensure they meet the stringent criteria required for downstream high-throughput screening (HTS) campaigns.
“Our collaboration with B’SYS builds on Axxam’s long-standing expertise in the field of ion channels and electrophysiology,” said Ciriaco Maraschiello, CEO of Axxam. “By combining B’SYS’s specialized cell line portfolio with our HTS capabilities, we can deliver robust, ready-to-use cellular models that accelerate screening timelines and de-risk early-stage discovery.”
“Axxam’s clear interest in accessing our validated ion channel cell lines confirms their quality and relevance. By validating selected B’SYS lines on Axxam’s complementary high-throughput platforms, both companies benefit: Axxam broadens its offering, while B’SYS gains visibility and new licensing opportunities,” said Daniel Konrad, CEO of B’SYS. “This collaboration fosters synergies in screening workflows and client outreach, enabling more robust and flexible solutions for ion channel drug discovery.”
About Axxam S.p.A.
Axxam S.p.A. is a leading provider of integrated discovery services across the life sciences industry. Within the drug discovery disciplines, we support pharma, biotech companies, start-ups, patient foundations as well as academic groups in their journey from hit identification to lead generation, regardless of the therapeutic area and target class. Our services include assay development, high-throughput screening, using either Axxam’s high quality compound collections (synthetic and natural) or those provided by clients, hit validation, hit-to-lead and compound management. The same science-driven approach is also applied to identify new bioactive compounds for crop protection, animal health, food, beverage, pet food, cosmetic and perfume industries. For more information, visit www.axxam.com.
About B'SYS GmbH
B’SYS GmbH is a Swiss-based CRO specializing in ion channel pharmacology at the intersection of cellular electrophysiology and preclinical drug development. Its validated portfolio of human ion channel-expressing cell lines is supported by a suite of in vitro platforms, including manual and automated patch clamp, fluorescence-based screening, and CiPA-compliant assays. B’SYS provides GLP-compliant studies and licenses ion channel reagents to support discovery and profiling efforts. With expertise in target validation, safety pharmacology and assay development, B’SYS contributes to safer, more effective therapeutics and advances next-generation bioactives across health, nutrition, recreation, and environmental applications. For more information, visit www.bsys.ch.
Media Contacts
Axxam S.p.A.
Antonella Solia
(Head, Marketing and Lead Generation)
antonella.solia.as@axxam.com
B’SYS GmbH
Ellen Braksator
(Leader Scientific Marketing, deputy CSO)
ellen.braksator@bsys.ch